Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Joseph Melenhorst

Showing results (1-10 of 92) with videos related to

Pageof 10
Sort By:
Cytotherapy|September 3, 2013
Regulatory T cells from another bench: ready for the bedside?J Joseph Melenhorst
Cytotherapy|November 12, 2009
Optimizing T-cell expansion: have we reached the limit?J Joseph Melenhorst
Blood|October 16, 2012
LGL: a disease rediscoveredJ Joseph Melenhorst
Nature Cancer|December 17, 2024
Navigating CAR-T cell therapy long-term complicationsCéline Grégoire, J Joseph Melenhorst
Blood Science (Baltimore, Md.)|April 11, 2022
CT103A, a forward step in multiple myeloma immunotherapiesJie Xu, J Joseph Melenhorst
Blood|June 12, 2010
Minor histocompatibility antigen discovery: turning up the HEATRA John Barrett, J Joseph Melenhorst
Journal for Immunotherapy of Cancer|March 14, 2024
Key role of CD4+ T cells in determining CD8 function during CAR-T cell manufactureJ Joseph Melenhorst, Beatriz C Oliveira
Cytotherapy|April 9, 2013
Innovation and opportunity for chimeric antigen receptor targeted T cellsJ Joseph Melenhorst, Bruce L Levine
Blood|May 8, 2020
CAR-T and ibrutinib vs CLL: sequential or simultaneous?Arnon P Kater, J Joseph Melenhorst
Blood|March 24, 2022
Do CARs finally hit the CLL road?Arnon P Kater, J Joseph Melenhorst
Pageof 10

Showing results (1-10 of 92) with videos related to

Sort By:
Pageof 10
Cytotherapy|September 3, 2013
Regulatory T cells from another bench: ready for the bedside?J Joseph Melenhorst
Cytotherapy|November 12, 2009
Optimizing T-cell expansion: have we reached the limit?J Joseph Melenhorst
Blood|October 16, 2012
LGL: a disease rediscoveredJ Joseph Melenhorst
Nature Cancer|December 17, 2024
Navigating CAR-T cell therapy long-term complicationsCéline Grégoire, J Joseph Melenhorst
Blood Science (Baltimore, Md.)|April 11, 2022
CT103A, a forward step in multiple myeloma immunotherapiesJie Xu, J Joseph Melenhorst
Blood|June 12, 2010
Minor histocompatibility antigen discovery: turning up the HEATRA John Barrett, J Joseph Melenhorst
Journal for Immunotherapy of Cancer|March 14, 2024
Key role of CD4+ T cells in determining CD8 function during CAR-T cell manufactureJ Joseph Melenhorst, Beatriz C Oliveira
Cytotherapy|April 9, 2013
Innovation and opportunity for chimeric antigen receptor targeted T cellsJ Joseph Melenhorst, Bruce L Levine
Blood|May 8, 2020
CAR-T and ibrutinib vs CLL: sequential or simultaneous?Arnon P Kater, J Joseph Melenhorst
Blood|March 24, 2022
Do CARs finally hit the CLL road?Arnon P Kater, J Joseph Melenhorst
Pageof 10